Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of EBITDA data on file, last reported at -$13.4 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 23.8% year-over-year to -$13.4 million; the trailing twelve-month figure through Dec 2025 stood at -$48.3 million (down 83.94% YoY), and the FY2025 full-year result was -$41.8 million, down 85.7% from the prior year.
• EBITDA fell to -$13.4 million in Q4 2025, from -$9.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.5 million in Q1 2022 to a low of -$15.3 million in Q1 2025.
• A 5-year average of -$6.6 million and a median of -$5.2 million in 2021 frame the typical range for EBITDA.
• Across the five-year window, EBITDA climbed 8.78% in 2022 and sank 270.32% in 2025, its largest moves.
• Tracing BNTC's EBITDA over 5 years: stood at -$4.8 million in 2021, then declined by 16.03% to -$5.6 million in 2022, then decreased by 23.48% to -$6.9 million in 2023, then plunged by 55.98% to -$10.8 million in 2024, then fell by 23.8% to -$13.4 million in 2025.
• Business Quant data shows BNTC's EBITDA at -$13.4 million in Q4 2025, -$9.8 million in Q3 2025, and -$9.8 million in Q2 2025.